ScripMultiple Chinese developers of antibody-drug conjugates (ADCs) are now turning their focus to bispecific candidates based on different target combinations as they look to diversify their expertise in
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daewoong, HanAll Co-Invest In Vinc